USANA Health Sciences, Inc. (NYSE:USNA) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. trimmed its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 55.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,697 shares of the company's stock after selling 36,062 shares during the quarter. JPMorgan Chase & Co. owned 0.15% of USANA Health Sciences worth $1,088,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in USNA. Pacer Advisors Inc. raised its position in USANA Health Sciences by 16.5% in the 3rd quarter. Pacer Advisors Inc. now owns 544,256 shares of the company's stock worth $20,638,000 after purchasing an additional 76,904 shares during the period. Pzena Investment Management LLC raised its position in USANA Health Sciences by 7.5% in the 3rd quarter. Pzena Investment Management LLC now owns 1,049,610 shares of the company's stock worth $39,801,000 after purchasing an additional 72,977 shares during the period. Allspring Global Investments Holdings LLC raised its position in USANA Health Sciences by 14,068.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company's stock worth $1,472,000 after purchasing an additional 38,547 shares during the period. Unison Advisors LLC purchased a new stake in USANA Health Sciences in the 3rd quarter worth about $683,000. Finally, Assenagon Asset Management S.A. raised its position in USANA Health Sciences by 13.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company's stock worth $4,702,000 after purchasing an additional 14,756 shares during the period. 54.25% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Price Performance

Shares of NYSE:USNA traded down $0.12 during trading on Friday, reaching $34.32. 122,116 shares of the company were exchanged, compared to its average volume of 88,033. The firm has a market capitalization of $654.04 million, a PE ratio of 12.13, a P/E/G ratio of 0.92 and a beta of 0.89. The business's fifty day simple moving average is $36.42 and its 200-day simple moving average is $38.47. USANA Health Sciences, Inc. has a 12-month low of $31.44 and a 12-month high of $52.75.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The business had revenue of $200.22 million for the quarter, compared to analyst estimates of $208.45 million. During the same period last year, the company posted $0.59 earnings per share. On average, sell-side analysts anticipate that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Insider Activity

In other news, Director Gilbert A. Fuller sold 675 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $37.71, for a total transaction of $25,454.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.33% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on USNA. DA Davidson increased their price objective on shares of USANA Health Sciences from $35.00 to $38.00 and gave the stock a "neutral" rating in a research report on Thursday, January 2nd. StockNews.com raised shares of USANA Health Sciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday, December 28th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.